Abstract: The present invention relates to Fc variants having increased affinity for Fc?RIIc, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Type:
Grant
Filed:
August 20, 2007
Date of Patent:
January 20, 2015
Assignee:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, Wei Dang, John R. Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes
Abstract: The present invention relates to the treatment of osteoarthritis and pain using IL-1? and IL-1? binding proteins, including anti-IL-1? and anti-IL-1? antibodies and engineered multivalent and multispecific IL-1? and IL-1? binding proteins.
Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
Type:
Grant
Filed:
February 1, 2010
Date of Patent:
November 11, 2014
Assignee:
Xencor, Inc.
Inventors:
Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
Abstract: An Fc variant of a parent Fc polypeptide, wherein said Fc variant exhibits altered binding to one or more Fc?Rs, wherein said Fc variant comprises at least one amino acid insertion in the Fc region of said parent Fc polypeptide.
Abstract: The present invention relates to a glycosylated immunoglobulin or a fragment thereof, in which an immunoglobulin variant, comprising one or more amino acid modifications selected from the group consisting of M160N, A195N, T243N, E265N, Y299T, F331T and Q346N, is additionally glycosylated, and a gene encoding the same.
Type:
Grant
Filed:
May 31, 2005
Date of Patent:
October 28, 2014
Assignee:
Korea Prime Pharm Co., Ltd
Inventors:
Yong-Hoon Chung, Ki-Wan Yi, Hoon-Sik Cho, Hong-Gyu Park, Kwang-Seong Kim
Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
Type:
Grant
Filed:
February 21, 2013
Date of Patent:
October 14, 2014
Assignee:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
Abstract: A humanized murine antibody is provided that binds to the human insulin receptor (HIR). The humanized murine antibody is suitable for use as a Trojan horse to deliver pharmaceutical agents to human organs and tissue that express the HIR. The humanized murine antibody is especially well suited for delivering neuropharmaceutical agents from the blood stream to the brain across the blood brain barrier (BBB). The humanized murine antibody may be genetically fused to the pharmaceutical agent or it may be linked to the pharmaceutical agent using an avidin-biotin conjugation system.
Type:
Grant
Filed:
May 1, 2008
Date of Patent:
October 14, 2014
Assignee:
The Regents of the University of California
Abstract: The invention relates to novel immunogens carrying conformationally discriminating epitopes (CDEs) and to immunization methods for producing antibodies that specifically recognize proteins with very closely related homologues. In particular, the invention relates to antibodies which are specific for either Fc?RIIb or Fc?RIIa.
Type:
Grant
Filed:
November 26, 2004
Date of Patent:
October 7, 2014
Assignee:
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
Inventors:
Robert Huber, Peter Sondermann, Uwe Jacob, Kerstin Wendt, Chiara Cabrele, Luis Moroder
Abstract: The present application relates to a variant Fc region comprising at least one modification relative to a wild-type human Fc region, where the modification selected from the group consisting of 434S, 252Y/428L, 252Y/434S, and 428L/434S, and the numbering is according to the EU index.
Type:
Grant
Filed:
February 1, 2010
Date of Patent:
October 7, 2014
Assignee:
Xencor, Inc.
Inventors:
Aaron Keith Chamberlain, Bassil I. Dahiyat, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
Type:
Grant
Filed:
December 20, 2011
Date of Patent:
October 7, 2014
Assignee:
ABBVIE Inc.
Inventors:
Chengbin Wu, Dominic J. Ambrosi, Chung-ming Hsieh, Tariq Ghayur
Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. Also, the present invention discloses a recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment, comprising culturing the transformant. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.
Type:
Grant
Filed:
November 13, 2004
Date of Patent:
September 30, 2014
Assignee:
Hanmi Science Co., Ltd
Inventors:
Sung Youb Jung, Jin Sun Kim, Geun Hee Yang, Se Chang Kwon, Gwan Sun Lee
Abstract: Hybrid nuclease molecules and methods for treating an immune-related disease or disorder in a mammal, and a pharmaceutical composition for treating an immune-related disease in a mammal.
Type:
Grant
Filed:
August 3, 2011
Date of Patent:
September 23, 2014
Assignee:
University of Washington
Inventors:
Jeffrey A. Ledbetter, Martha Hayden-Ledbetter, Keith Elkon, Xizhang Sun
Abstract: The present invention provides for IgG1 molecules with improved characteristics. In particular, substitution mutations are provided that, in combination, facilitate improved placental transfer, improved serum half-life and improved FcRn binding. Substitution mutations are also provided, that in combination, can be used to block FcRn function and thereby increase the clearance rates of other (endogenous or exogenous) IgGs, block placental transport of IgGs and have increased affinity/reduced pH dependence for FcRn binding.
Type:
Grant
Filed:
March 27, 2012
Date of Patent:
September 16, 2014
Assignee:
The Board of the University of Texas System
Abstract: The present invention provides antibodies which bind to an epitope in the extracellular domain of human CC chemokine receptor 4 (CCR4) and which are capable of inhibiting the binding of macrophage-derived chemokine (MDC) and/or thymus and activation regulated chemokine (TARC) to CCR4. Also provided are inter alia immunoconjugates and compositions comprising such antibodies and methods and uses involving such antibodies, particularly in the medical and diagnostic fields.
Type:
Grant
Filed:
March 27, 2013
Date of Patent:
September 2, 2014
Assignee:
Affitech Research AS
Inventors:
Lavinia Diana Cicortas Gunnarsson, Didrik Paus
Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.
Type:
Grant
Filed:
July 8, 2009
Date of Patent:
September 2, 2014
Assignee:
AbbVie Inc.
Inventors:
Tariq Ghayur, Jijie Gu, Peter C. Isakson
Abstract: The present invention relates to optimized Fc variants, methods for their generation, and antibodies and Fc fusions comprising optimized Fc variants.
Type:
Grant
Filed:
May 20, 2013
Date of Patent:
August 19, 2014
Assignee:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, Arthur J. Chirino, Wei Dang, John Desjarlais, Stephen K. Doberstein, Robert J. Hayes, Sher Bahadur Karki, Omid Vafa
Abstract: The present invention relates to Fc variants having decreased affinity for Fc?RIIb, methods for their generation, Fc polypeptides comprising optimized Fc variants, and methods for using optimized Fc variants.
Type:
Grant
Filed:
November 12, 2013
Date of Patent:
August 12, 2014
Assignee:
Xencor, Inc.
Inventors:
Gregory Alan Lazar, Wei Dang, John Desjarlais, Sher Bahadur Karki, Omid Vafa, Robert Hayes, Jost Vielmetter
Abstract: The present application relates to optimized IgG immunoglobulin variants, engineering methods for their generation, and their application, particularly for therapeutic purposes.
Type:
Grant
Filed:
October 31, 2007
Date of Patent:
August 12, 2014
Assignee:
Xencor, Inc.
Inventors:
Aaron Keith Chamberlain, Bassil I. Dahiyat, John Rudolph Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar
Abstract: The present invention relates to antibodies or fragments thereof that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than the antibodies or fragments thereof bind Fc?RIIA, particularly human Fc?RIIA. The present invention also provides the use of an anti-Fc?RIIB antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a B-cell malignancy, particularly, B-cell chronic lymphocytic leukemia or non-Hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an IgE-mediated allergic disorder, or one or more symptoms thereof. The invention provides methods of enhancing the therapeutic effect of therapeutic antibodies by administering the antibodies of the invention to enhance the effector function of the therapeutic antibodies. The invention also provides methods of enhancing efficacy of a vaccine composition by administering the antibodies of the invention.
Type:
Grant
Filed:
June 26, 2007
Date of Patent:
July 22, 2014
Assignee:
MacroGenics, Inc.
Inventors:
Leslie S. Johnson, Ling Huang, Robyn Gerena
Abstract: The present invention relates to methods of treatment, prevention, management or amelioration of one or more symptoms of diseases or disorders associated with CD20 expression that encompass administration of a combination of: (A) one or more antibodies that specifically bind Fc?RIIB, particularly human Fc?RIIB, with greater affinity than said antibodies bind Fc?RIIA, and (B) one or more antibodies that specifically bind to CD20. Such methods include methods of treating, preventing, managing or ameliorating one or more symptoms of a B cell related disease or disorder or an inflammatory disorder. The invention also provides pharmaceutical compositions comprising an anti-Fc?RIIB antibody and an anti-CD20 antibody.